Organic solvent-free benznidazole nanosuspension as an approach to a novel pediatric formulation for Chagas disease

Aim: Benznidazole (BNZ), a class-II drug, is the primary treatment for Chagas disease, but its low aqueous solubility presents challenges in formulation and efficacy. Nanosuspensions (NS) could potentially address these issues.
Methods: BNZ-NS were prepared using a simple, organic solvents-free nano-milling approach. Physicochemical characterizations were conducted on both NS and lyophilized solid-state BNZ-nanocrystals (NC).
Results: BNZ-NS exhibited particle size <500 nm, an acceptable polydispersity index (0.23), high Z-potential, and physical stability for at least 90 days. BNZ-NC showed tenfold higher solubility than pure BNZ. Dissolution assays revealed rapid BNZ-NS dissolution. BNZ-NC demonstrated biocompatibility on an eukaryotic cell and enhanced BNZ efficacy against trypomastigotes of Trypanosoma cruzi.
Conclusion: BNZ-NS offers a promising alternative, overcoming limitations associated with BNZ for optimized pharmacotherapy.
Novel nanosuspension of BNZ was produced without the use of organic solvents using a top-down method.
The aqueous solubility of BNZ-NS was found to be ten-times higher than its intrinsic solubility.
BNZ-NS exhibited improved in vitro dissolution behavior compared with crushed commercial tablets.
BNZ-NS demonstrated physical stability for 90 days under refrigerator and room temperature conditions.
BNZ-NS showed improved toxicity profiles and efficacy against Trypanosoma cruzi.